CN1634073A - Orally disintegrating tablet of levofloxacin and its pharmaceutical salt - Google Patents
Orally disintegrating tablet of levofloxacin and its pharmaceutical salt Download PDFInfo
- Publication number
- CN1634073A CN1634073A CN 200410079331 CN200410079331A CN1634073A CN 1634073 A CN1634073 A CN 1634073A CN 200410079331 CN200410079331 CN 200410079331 CN 200410079331 A CN200410079331 A CN 200410079331A CN 1634073 A CN1634073 A CN 1634073A
- Authority
- CN
- China
- Prior art keywords
- levofloxacin
- oral cavity
- disintegration tablet
- cavity disintegration
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 title claims abstract description 37
- 229960003376 levofloxacin Drugs 0.000 title claims abstract description 37
- 150000003839 salts Chemical class 0.000 title claims abstract description 18
- 239000006191 orally-disintegrating tablet Substances 0.000 title abstract 5
- 239000000463 material Substances 0.000 claims abstract description 17
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 12
- 239000000314 lubricant Substances 0.000 claims abstract description 9
- 210000000214 mouth Anatomy 0.000 claims description 46
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 39
- 239000003814 drug Substances 0.000 claims description 38
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 26
- 108010011485 Aspartame Proteins 0.000 claims description 19
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 19
- 229930195725 Mannitol Natural products 0.000 claims description 19
- 239000000605 aspartame Substances 0.000 claims description 19
- 235000010357 aspartame Nutrition 0.000 claims description 19
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 19
- 229960003438 aspartame Drugs 0.000 claims description 19
- 239000000594 mannitol Substances 0.000 claims description 19
- 235000010355 mannitol Nutrition 0.000 claims description 19
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 18
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 18
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 18
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 108010010803 Gelatin Proteins 0.000 claims description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 16
- 239000008273 gelatin Substances 0.000 claims description 16
- 229920000159 gelatin Polymers 0.000 claims description 16
- 235000019322 gelatine Nutrition 0.000 claims description 16
- 235000011852 gelatine desserts Nutrition 0.000 claims description 16
- 239000003094 microcapsule Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 235000019359 magnesium stearate Nutrition 0.000 claims description 13
- 239000004925 Acrylic resin Substances 0.000 claims description 11
- 229920000178 Acrylic resin Polymers 0.000 claims description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 9
- -1 effervescent Substances 0.000 claims description 9
- CAOOISJXWZMLBN-PPHPATTJSA-N htn0d03vrz Chemical compound Cl.C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 CAOOISJXWZMLBN-PPHPATTJSA-N 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000000741 silica gel Substances 0.000 claims description 9
- 229910002027 silica gel Inorganic materials 0.000 claims description 9
- 239000000945 filler Substances 0.000 claims description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 8
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 8
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 7
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 7
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 7
- 239000011734 sodium Substances 0.000 claims description 7
- ONDRRTIAGBDDKP-PPHPATTJSA-N 294662-18-3 Chemical compound CC(O)C(O)=O.C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 ONDRRTIAGBDDKP-PPHPATTJSA-N 0.000 claims description 6
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 5
- 239000011248 coating agent Substances 0.000 claims description 5
- 238000000576 coating method Methods 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 239000001856 Ethyl cellulose Substances 0.000 claims description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 4
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 4
- 229920001249 ethyl cellulose Polymers 0.000 claims description 4
- 235000018102 proteins Nutrition 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 235000010265 sodium sulphite Nutrition 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 4
- 235000015165 citric acid Nutrition 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 229920002521 macromolecule Polymers 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- 229920001817 Agar Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 239000008272 agar Substances 0.000 claims description 2
- 235000010419 agar Nutrition 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- 239000010238 camphora Substances 0.000 claims description 2
- 229940025250 camphora Drugs 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 150000001896 cresols Chemical class 0.000 claims description 2
- 238000004132 cross linking Methods 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 2
- DUYAAUVXQSMXQP-UHFFFAOYSA-N ethanethioic S-acid Chemical compound CC(S)=O DUYAAUVXQSMXQP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 229960001855 mannitol Drugs 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 claims description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 2
- 229940085605 saccharin sodium Drugs 0.000 claims description 2
- 229940083542 sodium Drugs 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 229960002920 sorbitol Drugs 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 2
- 229940013618 stevioside Drugs 0.000 claims description 2
- 235000019202 steviosides Nutrition 0.000 claims description 2
- 229960004793 sucrose Drugs 0.000 claims description 2
- 229940035024 thioglycerol Drugs 0.000 claims description 2
- 235000010384 tocopherol Nutrition 0.000 claims description 2
- 239000011732 tocopherol Substances 0.000 claims description 2
- 229960001295 tocopherol Drugs 0.000 claims description 2
- 229930003799 tocopherol Natural products 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 abstract 3
- 239000004067 bulking agent Substances 0.000 abstract 1
- 239000000796 flavoring agent Substances 0.000 abstract 1
- 235000013355 food flavoring agent Nutrition 0.000 abstract 1
- 238000000034 method Methods 0.000 description 16
- 239000002671 adjuvant Substances 0.000 description 11
- 238000007907 direct compression Methods 0.000 description 10
- 235000019658 bitter taste Nutrition 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 4
- 210000002200 mouth mucosa Anatomy 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 208000019505 Deglutition disease Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229920001038 ethylene copolymer Polymers 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000588923 Citrobacter Species 0.000 description 1
- 102000003844 DNA helicases Human genes 0.000 description 1
- 108090000133 DNA helicases Proteins 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 235000015250 liver sausages Nutrition 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000009702 powder compression Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to an orally disintegrating tablet of levofloxacin and its pharmaceutical salt which comprises physiologically effective amount of Levofloxacin or its medicinal salts and / or pharmaceutically acceptable carriers suitable for preparing orally disintegrating tablet, wherein the pharmaceutically acceptable carriers suitable for preparing orally disintegrating tablet include macromolecular material, bulking agent, crumbling agent, effervescent agent, lubricating agent, flavoring agent and other pharmaceutically acceptable carriers suitable for preparing orally disintegrating tablets.
Description
Technical field:
The present invention relates to field of medicaments, be particularly related to levofloxacin and biological or pharmaceutically acceptable be the pharmaceutical salts of active component with the levofloxacin, comprise oral cavity disintegration tablet of levofloxacin hydrochloride, levofloxacin lactate, Levofloxacin M. S. A and preparation method thereof.When the patient took this medicine, water or only need to take medicine with low amounts of water not need not to chew, and disintegrate in 5 seconds to 60 seconds in the oral cavity is borrowed and swallowed power, and medicine is gone into the stomach onset.
Background technology:
Oral cavity disintegration tablet is a kind of new pharmaceutical dosage forms, English " Orally disintegratingtables " by name.U.S. FDA has been ratified this dosage form listing, and reason is: make things convenient for part crowd medication, as the patient's medication under old man, child, dysphagia or the special environment.
Oral cavity disintegration tablet definition: be that a kind of water that do not need in the oral cavity can disintegrate or dissolved tablet.Specification requirement: 1. should be in the oral cavity rapidly disintegrate, no grittiness, good mouthfeel, swallow easily, to the oral mucosa nonirritant.Should stipulate under the character item in the quality standard: disintegrate rapidly, no grittiness, good mouthfeel in the oral cavity; 2. set up suitable disintegration time mensuration method and limit, and be incorporated into standard; 3. to insoluble medicine, should set up suitable dissolution determination method and limit; 4. other should meet general rule requirement under the tablet item.
The characteristics of oral cavity disintegration tablet: 1. absorption is fast, bioavailability is high; 2. instructions of taking does not need water 3. intestinal is residual few, few side effects; 4. avoid the first pass effect of liver sausage.
Levofloxacin or its pharmaceutical salts are quinolione class antibiotic, and its antibacterial activity is about 2～8 times of ofloxacin.Has has a broad antifungal spectrum, the characteristics that antibacterial action is strong, to most of enterobacteriaceae lactobacteriaceaes, as escherichia coli, Klebsiella, Serratia, Proteus, Shigella, Salmonella, citrobacter, acinetobacter and Pseudomonas aeruginosa, hemophilus influenza, gram-negative bacterias such as gonococcus have stronger antibacterial activity, for example levofloxacin hydrochloride is very responsive to clinical isolating Bacillus typhi and dysentery bacterium, levofloxacin lactate is to having shown very strong antibacterial activity to Shigella in the gram negative bacteria, very responsive to Salmonella, to part methicillin-sensitivity staphylococcus, streptococcus pneumoniae, micrococcus scarlatinae, gram positive bacteria and legionella such as Hemolytic streptococcus, mycoplasma, chlamydia etc. also have good antibacterial action, but relatively poor to anaerobe and enterococcal effect.It mainly acts on the A subunit of bacterial cell DNA helicase, suppresses the synthetic of DNA and duplicates and cause antibacterial death.
The oral formulations of existing levofloxacin and pharmaceutical salts thereof comprises tablet, capsule etc., all to use water delivery service, and, levofloxacin and pharmaceutical salts thereof have the bitterness of strong row and have GI irritation, the invention provides a kind of levofloxacin and pharmaceutical salts oral cavity disintegration tablet thereof, this tablet get by direct compression, and advantage is patient when taking this medicine, not water or only need take medicine with low amounts of water, need not to chew, disintegrate in 5 seconds to 60 seconds in the oral cavity is borrowed and is swallowed power, and medicine is gone into the stomach onset, no bitterness, nonirritant is treated patient timely and effectively, saves trouble.
Summary of the invention:
The present invention makes oral cavity disintegration tablet with levofloxacin, levofloxacin hydrochloride, levofloxacin lactate and Levofloxacin M. S. A, has technically overcome bitter taste of drug, and disintegrate has rapidly improved bioavailability of medicament greatly in the oral cavity.
Levofloxacin oral cavity disintegration tablet of the present invention by active component levofloxacin or its pharmaceutical salts as: levofloxacin hydrochloride, levofloxacin lactate, Levofloxacin M. S. A and auxiliary element are formed.Every contains active component 0.05-0.2g, is preferably 0.1g (in levofloxacin), and all the other are auxiliary element.Auxiliary element is the medicine acceptable carrier that is fit to make oral cavity disintegration tablet, mainly comprises macromolecular material, filler, disintegrating agent, effervescent, lubricant, correctives etc.Feature of the present invention also is to adopt packaging technique and preconditioning technique to prepare the microcapsule of levofloxacin, and then makes oral cavity disintegration tablet.
Oral cavity disintegration tablet require disintegrate rapidly, no husky large sense, good mouthfeel, swallow easily, to the oral mucosa nonirritant, so having relatively high expectations adjuvant.Adjuvant commonly used has: acrylic resin, ethyl cellulose, gelatin, cellulose, acrylate copolymer, ethylene copolymer, cross-linking sodium carboxymethyl cellulose, crospolyvinylpyrrolidone, carboxymethyl starch sodium, microcrystalline Cellulose, low-substituted hydroxypropyl cellulose, handle agar, citric acid, sodium bicarbonate, mannitol, Camphora, lactose, erythrol, maltose alcohol, saccharin sodium, protein sugar, sucrose, Mentholum, aspartame, xylitol, mannitol, protein sugar, stevioside, sucrose, sorbitol, vitamin C, sodium sulfite, sodium sulfite, pyrosulfite, sodium thiosulfate, different VC, thiourea, cysteine, methionine, thiacetic acid., thioglycerol, butylated hydroxyarisol, two fourth cresols, PG, tocopherol, lecithin, sodium lauryl sulphate, Pulvis Talci, magnesium stearate, micropowder silica gel, Opadry
II, ethanol, water, gelatin, aspartame, Fructus Citri tangerinae essence, adjuvants such as Herba Menthae essence.
Select adjuvant significant to oral cavity disintegration tablet, preferred adjuvant can make disintegrate rapidly, no husky large sense, good mouthfeel, swallow easily, to the oral mucosa nonirritant, the present invention selects adjuvant, serves as preferred with microcrystalline Cellulose (MCC), mannitol, crospolyvinylpyrrolidone (PVPP), low-substituted hydroxypropyl cellulose (L-HPC), citric acid, sodium bicarbonate, magnesium stearate, micropowder silica gel, gelatin, acrylic resin, aspartame, flavoring orange essence, Herba Menthae essence.
Oral cavity disintegration tablet of the present invention preferably consists of:
Levofloxacin or its pharmaceutical salts 20-50%
Macromolecular material 1-10%
Filler 30-70%
Disintegrating agent 2-15%
Effervescent 2-10%
Correctives 0.5-15%
Lubricant 0.1-3%
Wherein macromolecular material is used to wrap up levofloxacin or its pharmaceutical salts, to cover bitterness, described macromolecular material is selected from: gelatin, acrylic resin, ethyl cellulose, filler is selected from: microcrystalline Cellulose, lactose, mannitol, disintegrating agent is selected from: low-substituted hydroxypropyl cellulose, crospolyvinylpyrrolidone, carboxymethyl starch sodium, effervescent is selected from: citric acid, sodium bicarbonate, correctives are selected from, aspartame, Fructus Citri tangerinae essence, Herba Menthae essence, and lubricant is selected from: magnesium stearate, micropowder silica gel.
Particularly preferred prescription consists of: be made up of following prescription for 1000, every contains active component and is about 0.1g (in levofloxacin)
Levofloxacin M. S. A 128g
Acrylic resin 12.8g
Mannitol 71.2g
Microcrystalline Cellulose 60g
Low-replacement hydroxypropyl cellulose 5g
Crospolyvinylpyrrolidone 10g
Sodium bicarbonate 4g
Citric acid 5g
Aspartame 2g
Magnesium stearate 1g
Micropowder silica gel 1g
More than Pei Fang oral cavity disintegration tablet be with levofloxacin or its pharmaceutical salts as: levofloxacin hydrochloride, levofloxacin lactate or Levofloxacin M. S. A are rolled into micron-sized granule with macromolecular material and further make oral cavity disintegration tablet again, the oral cavity disintegration tablet that this levofloxacin wraps up with macromolecular material, it consists of: the micron-sized granule that levofloxacin or its pharmaceutical salts are rolled into natural or synthetic macromolecular material is as active part, in addition the preferred filler of the present invention, disintegrating agent, effervescent, lubricant, correctives.
The micron-sized granule method for making that macromolecular material is rolled into is seen Fig. 1:
Wherein to join method as follows for [1] diluent: diluent is Na
2SO
4Solution, its concentration is by the Na in the cohesion bag system
2SO
4Concentration (as being a%) adds 1.5%[and gets (a+1.5) %], the diluent volume is 3 times of cohesion bag system cumulative volume, the diluent temperature is 15 ℃.Used diluent excessive concentration or low excessively can make the agglomerating or dissolving of cohesion capsular adhesion.
Also can adopt fluidized bed coating, medicine is rolled into microcapsule, preparation method as following microcapsule: IV150g is dissolved in 95% ethanol with macromolecule coating material acrylic resin, by fluid bed above-mentioned solution slowly is sprayed on medicine (1500g) surface, and medicine is wrapped up.Make microcapsule.
The microcapsule that above method makes with can make oral cavity disintegration tablet of the present invention by direct compression process after other adjuvant mixes.
Oral cavity disintegration tablet of the present invention, employing be the technical method preparation of pharmaceutics routine, as using direct compression process, wet method system granule is pressed disc method again.
Levofloxacin oral cavity disintegration tablet of the present invention, especially the oral cavity disintegration tablet that particularly preferred prescription is formed is compared with existing dosage form has plurality of advantages: when the patient takes this medicine, water or only need to take medicine not with low amounts of water, need not to chew, disintegrate in 5 seconds to 60 seconds in the oral cavity, borrow and swallow power, medicine is gone into the stomach onset.Take medicine and save trouble, save the trouble with the water delivery service medicine, treatment in time, and is effective; Make things convenient for part crowd medication, as the patient's medication under old man, child, dysphagia or the special environment.For the particularly preferred levofloxacin oral cavity disintegration tablet of the present invention, also have the following advantages especially: disintegrate is rapid, no grittiness, and no bitterness, good mouthfeel absorbs rapidly nonirritant, bioavailability height.
Description of drawings:
The micron-sized granule preparation flow chart that Fig. 1 is rolled into for macromolecular material.
The specific embodiment:
By the following examples, the invention will be further described.
Embodiment 1:
Adopt direct powder compression to prepare oral cavity disintegration tablet, it is as follows to write out a prescription:
Levofloxacin hydrochloride 112
Lactose 30g
Mannitol 53g
Microcrystalline Cellulose 80g
Low-replacement hydroxypropyl cellulose 20g
Magnesium stearate 1g
Micropowder silica gel 1g
Aspartame 1g
Fructus Citri tangerinae essence 2g
Said medicine and adjuvant crossed respectively mix direct compression behind 80 mesh sieves and promptly get 1000.The oral cavity disintegration tablet smooth in appearance that this prescription makes be disintegratable in the rapid 10s of disintegrate, but mouthfeel is general.
Embodiment 2:
Adopt the direct compression method to prepare oral cavity disintegration tablet.Disintegrating agent is selected microcrystalline Cellulose, low-replacement hydroxypropyl cellulose and crospolyvinylpyrrolidone.The proportioning of microcrystalline Cellulose/low-replacement hydroxypropyl cellulose/crospolyvinylpyrrolidone is: 9: 1: 2, correctives was selected aspartame and Herba Menthae essence.
Method is as follows:
With Levofloxacin M. S. A 128g, mannitol 83g, microcrystalline Cellulose 45g, low-replacement hydroxypropyl cellulose 5g, crospolyvinylpyrrolidone 10g, sodium bicarbonate 10g, citric acid 12g, aspartame 3g, Herba Menthae essence 2g, magnesium stearate 2g.Medicine and adjuvant mixing direct compression are promptly got 1000.The oral cavity disintegration tablet that makes, the rapid disintegrate of 30s does not have husky large sense, no bitterness.
Embodiment 3:
Disintegrating agent is selected microcrystalline Cellulose and crospolyvinylpyrrolidone for use, and proportioning is 9: 1; With gelatin, mannitol and aspartame is correctives, and the proportioning of gelatin/mannitol/Aspartane is 0.5: 1: 0.1.With sodium bicarbonate and citric acid is effervescent.It is as follows to write out a prescription:
Dlactic acid levofloxacin 125g
Mannitol 37g
Microcrystalline Cellulose 90g
Crospolyvinylpyrrolidone 10g
Sodium bicarbonate 8g
Citric acid 10g
Gelatin 15g
Magnesium stearate 2g
Aspartame 3g
Preparation method: medicine and gelatin, mannitol (3g) and aspartame are crossed 60 mesh sieves respectively, gelatin is dissolved in an amount of distilled water, heating makes its dissolving.Under agitation medicine, mannitol (3g) and aspartame are added, put 70～80 ℃ of stirring evaporates to dryness in the water-bath, crushing screening.Promptly get 1000 with other adjuvant mixing direct compression.The oral cavity disintegration tablet smooth in appearance that makes, glossy; Disintegrate is rapid, does not have husky large sense, and mouthfeel is general.
Embodiment 4:
Adopt method for pretreating, promptly use natural or synthetic high molecular polymer (gelatin, cellulose, acrylate copolymer or ethylene copolymer etc.) that medicine is rolled into the micron order granule, to improve the disagreeable taste of medicine.This test adopts single coacervation with gelatin medicine to be wrapped up.Concrete grammar is as follows:
Take by weighing in the gelatin 20g adding 300ml distilled water and soak swelling, melt into rubber cement in 70 ℃ of water-baths is dissolved in levofloxacin hydrochloride 112g in the gelatin solution, stirs.Acetum 50 ℃ of addings 10% is regulated PH to 3.5～3.8, slowly adds 20% Na under middling speed stirs
2SO
4(160ml) make the capsule cohesion.Add the diluent (the diluent temperature is 15 ℃) of 3 times of amounts, make the capsule sedimentation.NaOH with 20% regulates PH to 8～9, in adding 37% formalin (50ml) below 15 ℃ capsule is solidified.Leave standstill, sucking filtration is put the vacuum drying oven drying in 55 ℃, promptly gets microcapsule.
Add mannitol 48g then, microcrystalline Cellulose (MCC) 80g, crospolyvinylpyrrolidone (PVPP) 20g, citric acid 8g, sodium bicarbonate 6g, aspartame 2g, Fructus Citri tangerinae essence 2g, magnesium stearate 2g, direct compression promptly get 1000.
According to the oral cavity disintegration tablet that this prescription makes, disintegrate is rapid, does not have husky large sense, no bitterness.
Embodiment 5:
Adopt fluidized bed coating, medicine is rolled into direct compression behind the microcapsule.
1. the preparation of microcapsule
IV150g is dissolved in 95% ethanol with macromolecule coating material acrylic resin, by fluid bed above-mentioned solution slowly is sprayed on medicine (1500g) surface, and medicine is wrapped up.Make microcapsule.
2. the microcapsule and other adjuvant mixing direct compression that make of tabletting.It is as follows to write out a prescription:
Levofloxacin M. S. A 128g
Acrylic resin 12.8g
Mannitol 71.2g
Microcrystalline Cellulose 60g
Low-replacement hydroxypropyl cellulose 5g
Crospolyvinylpyrrolidone 10g
Sodium bicarbonate 4g
Citric acid 5g
Aspartame 2g
Magnesium stearate 1g
Micropowder silica gel 1g
By the oral cavity disintegration tablet that this method makes, smooth in appearance, rapid at intraoral disintegration, disintegrate rapidly in the 40s.No husky large sense, non-stimulated in mouthful to oral mucosa, good mouthfeel.
Claims (10)
1, the oral cavity disintegration tablet of a kind of levofloxacin or its pharmaceutical salts is characterized in that, by the levofloxacin of physiology effective dose or its pharmaceutical salts and the medicine acceptable carrier that is fit to make oral cavity disintegration tablet form.
2, the oral cavity disintegration tablet of claim 1 is characterized in that, the described medicine acceptable carrier that is fit to make oral cavity disintegration tablet is macromolecular material, filler, disintegrating agent, effervescent, lubricant and correctives.
3, the oral cavity disintegration tablet of claim 2 is characterized in that, described medicine acceptable carrier is selected from: gelatin, acrylic resin, ethyl cellulose, cross-linking sodium carboxymethyl cellulose, crospolyvinylpyrrolidone, carboxymethyl starch sodium, microcrystalline Cellulose, low-substituted hydroxypropyl cellulose, handle agar, citric acid, sodium bicarbonate, mannitol, Camphora, lactose, erythrol, maltose alcohol, saccharin sodium, protein sugar, sucrose, Mentholum, aspartame, xylitol, mannitol, protein sugar, stevioside, sucrose, sorbitol, vitamin C, sodium sulfite, sodium sulfite, pyrosulfite, sodium thiosulfate, different VC, thiourea, cysteine, methionine, thiacetic acid., thioglycerol, butylated hydroxyarisol, two fourth cresols, PG, tocopherol, lecithin, sodium lauryl sulphate, Pulvis Talci, magnesium stearate, micropowder silica gel, Opadry
II, ethanol, water, aspartame, Fructus Citri tangerinae essence, Herba Menthae essence.
4, the oral cavity disintegration tablet of claim 2 is characterized in that, it consists of:
Levofloxacin or its pharmaceutical salts 20-50%
Macromolecular material 1-10%
Filler 30-70%
Disintegrating agent 2-15%
Effervescent 2-10%
Correctives 0.5-15%
Lubricant 0.1-3%
5, the oral cavity disintegration tablet of claim 4, it is characterized in that described macromolecular material is selected from: gelatin, acrylic resin, ethyl cellulose, filler is selected from: microcrystalline Cellulose, lactose, mannitol, disintegrating agent is selected from: low-substituted hydroxypropyl cellulose, crospolyvinylpyrrolidone, carboxymethyl starch sodium, effervescent is selected from: citric acid, sodium bicarbonate, correctives are selected from aspartame, Fructus Citri tangerinae essence, Herba Menthae essence, and lubricant is selected from: magnesium stearate, micropowder silica gel.
6, the oral cavity disintegration tablet of claim 4 is characterized in that, form by following prescription for 1000,
Levofloxacin M. S. A 128g
Acrylic resin 12.8g
Mannitol 71.2g
Microcrystalline Cellulose 60g
Low-replacement hydroxypropyl cellulose 5g
Crospolyvinylpyrrolidone 10g
Sodium bicarbonate 4g
Citric acid 5g
Aspartame 2g
Magnesium stearate 1g
Micropowder silica gel 1g
7, the oral cavity disintegration tablet of claim 4 is characterized in that, form by following prescription for 1000,
Levofloxacin hydrochloride 112g
Gelatin 20g
Mannitol 48g
Microcrystalline Cellulose 80g
Crospolyvinylpyrrolidone 20g
Citric acid 8g
Sodium bicarbonate 6g
Aspartame 2g
Fructus Citri tangerinae essence 2g
Magnesium stearate 2g
8, the oral cavity disintegration tablet of claim 4 is characterized in that, the pharmaceutical salts of described levofloxacin is selected from: levofloxacin hydrochloride, levofloxacin lactate, Levofloxacin M. S. A.
9, the preparation method of the oral cavity disintegration tablet of claim 4 is characterized in that, medicine is rolled into microcapsule with macromolecular material, microcapsule and filler, disintegrating agent, effervescent, correctives, mix lubricant, tabletting.
10, the preparation method of claim 9, it is characterized in that the preparation process following steps of microcapsule: IV150g is dissolved in 95% ethanol with macromolecule coating material acrylic resin, by fluid bed above-mentioned solution slowly is sprayed on the 1500g medical surfaces, with the medicine parcel, make microcapsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410079331 CN1634073A (en) | 2004-10-01 | 2004-10-01 | Orally disintegrating tablet of levofloxacin and its pharmaceutical salt |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410079331 CN1634073A (en) | 2004-10-01 | 2004-10-01 | Orally disintegrating tablet of levofloxacin and its pharmaceutical salt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1634073A true CN1634073A (en) | 2005-07-06 |
Family
ID=34847100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410079331 Pending CN1634073A (en) | 2004-10-01 | 2004-10-01 | Orally disintegrating tablet of levofloxacin and its pharmaceutical salt |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1634073A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102784121A (en) * | 2012-08-23 | 2012-11-21 | 海南卫康制药(潜山)有限公司 | Levofloxacin composition freeze-dried orally disintegrating tablets and preparation method thereof |
| CN104825411A (en) * | 2015-06-08 | 2015-08-12 | 孙莉新 | Levofloxacin mesylate orally disintegrating tablet and preparation method thereof |
| CN108567761A (en) * | 2018-07-25 | 2018-09-25 | 江苏黄河药业股份有限公司 | A kind of Levofloxacin Hydrochloride Capsules and preparation method thereof |
| WO2020255837A1 (en) * | 2019-06-17 | 2020-12-24 | 東和薬品株式会社 | Timed-elution masking particles and oral pharmaceutical composition containing same |
-
2004
- 2004-10-01 CN CN 200410079331 patent/CN1634073A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102784121A (en) * | 2012-08-23 | 2012-11-21 | 海南卫康制药(潜山)有限公司 | Levofloxacin composition freeze-dried orally disintegrating tablets and preparation method thereof |
| CN104825411A (en) * | 2015-06-08 | 2015-08-12 | 孙莉新 | Levofloxacin mesylate orally disintegrating tablet and preparation method thereof |
| CN108567761A (en) * | 2018-07-25 | 2018-09-25 | 江苏黄河药业股份有限公司 | A kind of Levofloxacin Hydrochloride Capsules and preparation method thereof |
| WO2020255837A1 (en) * | 2019-06-17 | 2020-12-24 | 東和薬品株式会社 | Timed-elution masking particles and oral pharmaceutical composition containing same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1130194C (en) | Solid pharmaceutical preparation | |
| CN1173694C (en) | Pharmaceutical compositions for the treatment of acute diseases | |
| CN1042299C (en) | Improved oral dosage forms of dideoxy purine nucleosides | |
| CN1109328A (en) | Sustained release formulations for 24 hour release of metoprolol | |
| CN1170358A (en) | Chewable dosage forms | |
| CN1366878A (en) | Texture screening granules containing active components | |
| CN1494434A (en) | Uses of sugar alcohol-containing spray-dried powder | |
| CN1303280A (en) | Stable dosage forms of fluoxetine and its enantiomers | |
| CN1586475A (en) | Vitamin C oral disintegration tablet and its preparing method | |
| CN1303989C (en) | Zinc gluconate oral disintegrating tablet and its preparation process | |
| CN1883456A (en) | Flavor-hidden pharmaceutical granule, preparation method and use thereof | |
| CN1631371A (en) | Oral administered bitter free powder of macrolide antibiotic, its prescription and preparation process | |
| CN1911211A (en) | Solid oral prepn. of leishajilan | |
| CN1634073A (en) | Orally disintegrating tablet of levofloxacin and its pharmaceutical salt | |
| CN1964699B (en) | Composition for oral ingestion in dry form and composition for oral ingestion in ready-to-use gel form | |
| CN1214784C (en) | Quick-releasing talbet in vagina and its preparing method | |
| CN1942183A (en) | Isosorbide-containing jelly preparation | |
| CN1634061A (en) | Pharmaceutical formulation of pseudoephenrine hydrochloride and its preparing process | |
| CN1414847A (en) | Sustained-releasing antihelmintic compositions comprising praziquantel | |
| CN114177142B (en) | Praxifloxacin enteric solid dispersion and preparation containing same | |
| CN1254240C (en) | Silibinin meglumine salt oral disintegration tablet preparation and its preparing method | |
| CN1634096A (en) | Notoginseng total saponin orally disintegrating tablet | |
| KR101501889B1 (en) | Orally disintegrating tablet containing low-dose ramosetron | |
| CN1586485A (en) | Cefaclor oral disintegration tablet | |
| CN1903183A (en) | Dispersion tablets of telbivudine and its prepn. method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |